Therapy News and Research

RSS

Oncology nurses explore how to better combat patient fatigue

They are key members of the healthcare team who face ongoing challenges on how best to provide optimum care to patients affected by cancer. Oncology nurses at The Cancer Institute of New Jersey continually strive to improve patient care and have recently explored how to better combat patient fatigue, the importance of documenting sleep-wake disturbances and the development of a toolkit to help patients better follow their oral treatment schedule during clinical trials.

23 Apr 2013

TSRI scientists find way to directly turn bone marrow stem cells into brain cells

In a serendipitous discovery, scientists at The Scripps Research Institute have found a way to turn bone marrow stem cells directly into brain cells.

23 Apr 2013

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.

23 Apr 2013

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).

From Medtronic 23 Apr 2013

State roundup: Calif. lawmakers push for health plan for immigrants in U.S. illegally

A selection of health policy stories from Massachusetts, California, Michigan, Texas, the District of Columbia, Pennsylvania, South Carolina and Tennessee.

23 Apr 2013

William Meehan wins AMSSM Foundation-ACSM Foundation Clinical Research Grant to study brain injury

William Meehan, MD, is the first recipient of the AMSSM Foundation-ACSM Foundation Clinical Research Grant for his research titled "A Randomized, Double-Blind, Placebo-Controlled Trial of Transcranial Light Emitting Diode Therapy for the Treatment of Chronic Concussive Brain Injury."

23 Apr 2013

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco in combination with another potential CF therapy, VX-661.

23 Apr 2013

NKI-AVL joins research consortium to develop MRI-guided radiation therapy system for cancer care

Elekta and Royal Philips Electronics announced today that The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital has signed an agreement to join a research group to advance the development of ground-breaking image-guided treatment technology for cancer care.

From Elekta 23 Apr 2013

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Pharmacyclics, Inc. announced today that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma, (RESONATE) was achieved on April 3, 2013.

23 Apr 2013

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

22 Apr 2013

UB researchers develop aniontransporters to trigger cancer cell apoptosis

The journal Accounts of Chemical Research, which has a profound impact on Chemistry and other related sciences, publishes on its current issue the article "Anion Transporters and Biological Systems", signed by Professor Ricardo Pérez Tomás, from the Department of Pathology and Experimental Therapy of the Faculty of Medicine at the University of Barcelona, Roberto Quesada, from the Department of Chemistry of the Sciences Faculty at the University of Burgos, and Philip A. Gale, from the University of Southampton, in the United Kingdom.

22 Apr 2013

Advances in treatment have improved the chances of survival for young patients with cancer

Over the years, advances in treatment have improved the chances of survival for young patients with cancer. But long-term survivors need to be aware of cancer treatments that may place them at increased risk of heart disease later in life.

22 Apr 2013

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Synta Pharmaceuticals Corp. announced today that the first patients have been treated in the randomized GALAXY-2 Phase 3 trial designed to evaluate docetaxel plus ganetespib, its investigational Hsp90 inhibitor, versus docetaxel alone for the second-line treatment of non-small cell lung adenocarcinoma.

22 Apr 2013

Xenon Pharmaceuticalsn receives BIOTECanada's Gold Leaf Company of the Year Award for 2013

Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded BIOTECanada's Gold Leaf Company of the Year Award for 2013.

22 Apr 2013

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a research study, conducted with an independent market research firm, that identified a significant unmet medical need for improved treatments for patients with chronic pain and dysphagia/odynophagia. In clinical practice, dysphagia is most often defined as difficulty in swallowing and odynophagia is defined as pain upon swallowing.

22 Apr 2013

First Edition: April 22, 2013

Today's headlines include reports ranging from how state leaders are dealing with the consequences of rejecting the health law's Medicaid expansion to how pending immigration reform proposals could ease the nation's physician shortage.

22 Apr 2013

MEDIAN Technologies selected as imaging solutions provider in phase II NSCLC clinical trial

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected as the imaging solutions and services provider in a new phase II clinical trial on Non Small Cell Lung Cancer (NSCLC).

22 Apr 2013

Sanovas introduces new surgical imaging technology, MicroCam

Sanovas Inc., a life science technology company developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today the launch of MicroCam™, its OEM "Plug & Play" micro imaging platform for endoscopic device applications.

22 Apr 2013

CI therapy appears to benefit children with cerebral palsy

Researchers at the University of Alabama at Birmingham (UAB) report that children with cerebral palsy who underwent Constraint Induced Movement therapy (CI therapy) saw a significant increase in grey matter volume in areas of the brain associated with movement.

22 Apr 2013

Non-invasive brain surgery: an interview with Dr Andres Lozano, University of Toronto

MR-guided focused ultrasound is a new technique that involves focusing 1024 beams of ultrasound through the skull to a focal point in the brain, very much like using the sun and a magnifying glass to burn a hole in a sheet of paper.

22 Apr 2013

Therapy News and Research

Oncology nurses explore how to better combat patient fatigue

TSRI scientists find way to directly turn bone marrow stem cells into brain cells

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

State roundup: Calif. lawmakers push for health plan for immigrants in U.S. illegally

William Meehan wins AMSSM Foundation-ACSM Foundation Clinical Research Grant to study brain injury

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

NKI-AVL joins research consortium to develop MRI-guided radiation therapy system for cancer care

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

UB researchers develop aniontransporters to trigger cancer cell apoptosis

Advances in treatment have improved the chances of survival for young patients with cancer

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Xenon Pharmaceuticalsn receives BIOTECanada's Gold Leaf Company of the Year Award for 2013

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

First Edition: April 22, 2013

MEDIAN Technologies selected as imaging solutions provider in phase II NSCLC clinical trial

Sanovas introduces new surgical imaging technology, MicroCam

CI therapy appears to benefit children with cerebral palsy

Non-invasive brain surgery: an interview with Dr Andres Lozano, University of Toronto

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News